Product Description
a small molecule inhibitor of dihydroorotate dehydrogenase (DHODH), potentiates activity of Gilteritinib and Cytarabine in preclinical models of AML; RP7214 is a novel and potent DHODH inhibitor that inhibited DHODH activity in enzyme and PHA induced HWB/PBMC proliferation with IC50 and EC50 values of 7.8 & 2.5/0.60 nM respectively. (Sourced from: https://rhizen.com/wp-content/uploads/2020/12/RP7214-combination-poster-AML-2019.pdf)
Mechanisms of Action: DHODH Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Rhizen
Company Location: Asia Pacific
Company Founding Year: 2008
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Preleukemia|Chronic Myelomonocytic Leukemia|Myelodysplastic Syndrome|Acute Monocytic Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Juvenile Myelomonocytic Leukemia,|Chronic Myeloid Leukemia|Communicable Diseases|COVID-19
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04680429 |
RP7214-2002 | P1 |
Completed |
Healthy Volunteers |
2021-07-17 |
2021-08-19 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT05246384 |
RP7214-2102 | P2 |
Withdrawn |
Myelodysplastic Syndrome|Preleukemia|Juvenile Myelomonocytic Leukemia,|Chronic Myeloid Leukemia|Acute Myeloid Leukemia|Acute Myelomonocytic Leukemia|Acute Monocytic Leukemia|Chronic Myelomonocytic Leukemia |
2024-12-01 |
2022-11-01 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
NCT05007236 |
RP7214-2101 | P2 |
Completed |
COVID-19|Communicable Diseases |
2022-03-25 |
2022-04-22 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |